105380A novel vascular stem cell product ANGICYTE for regenerative medicineClosedStudyInnovate UK"VascVersa (Versatile Vascular Stem Cells for Regenerative Medicine) Cardiovascular diseases are the top cause of death worldwide. There is an urgent need to find new treatments to repair damaged blood vessels as current approaches are not optimal. At VascVersa, we are committed to develop innovative regenerative medicine, and we have optimised a consistent way to manufacture highly pure vascular stem cells from a sample of blood. Our unique method of generation produces a stem cell therapy product ANGICYTE, of top quality with higher purity and superior growth capacity, when compared to other available cell products. These vascular stem cells can be grown up in our laboratory to provide large numbers for treatment. As all tissue repair requires blood supply, ANGICYTE can be harnessed to target areas of blood vessel injury and promote repair of damaged blood vessels. We have experimental evidence that our Vascular stem cells can be used as a cellular therapy promoting new blood vessel formation. We are developing a novel cell therapy product ANGICYTE for regenerative medicine. In the first phase, we will use ANGICYTE to target wound healing as it was a key area of demand identified in our market research (through the ICURe programme) and includes diabetic ulcers, pressure ulcers, burns, wounds, and chronic non-healing ulcers; however, ANGICYTE can also be applied to other vascular diseases in the heart, brain, and limbs, and this will be the focus of our second phase. This Innovate UK grant will provide much needed start-up funding to allow us to spin out our company, develop our technology into a clinical grade product and meet with regulatory agencies that will guide the future development of these stem cells to effectively treat patients."